Although some of these mutants have been proposed as candidate cancer-driving genes [17], unexpectedly, our analysis in rat epithelial cells and in human tumor cell lines failed to provide support for a gain-of-function effect for any of the four TRKB point mutations. This evidence concerns the gene NTRK2 and neoplasm.